JHVEPhoto / Shutterstock.com
Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva, generics, revenues, full-year results, generic competition, Copaxone, ProAir, generic sales, Kåre Schultz, research and development, R&D